Condition: Breast Cancer · Metastatic Cancer · Metastatic Breast Cancer · Sponsor: National Cancer Institute, Egypt
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
This description comes directly from the study's public registry record.
Rimoun R Boutrus, M.D. · +201061056900 · rimoun.boutrus@nci.cu.edu.eg
Joseph S Nayrouz, M.D. · +201272148324 · j_nayrouz@yahoo.com
Always discuss trial participation with your own doctor first.
| National Cancer Institute | Cairo, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06144346